Medication adherence is one of the most salient predictors of patient outcomes in the era following development of effective treatment for HIV infection. Evolving strategies to improve adherence, specifically incentive interventions and real-time medication monitoring, have shown some success in limited studies. Further investigation into incentive interventions for HIV-infected adolescents with poor medication adherence is necessary.
PRIMARY OBJECTIVE: * To describe the effects of a novel incentive intervention model on HIV-infected youths' patterns of antiretroviral medication adherence. SECONDARY OBJECTIVES: * To evaluate the feasibility of an outpatient incentive intervention model. * To assess participant satisfaction with the incentive intervention model. * To evaluate the effect of an outpatient incentive intervention model on targeted health behaviors (numbers of missed appointments and STI diagnoses). * To measure the effect of the incentive intervention on HIV viral load and CD4+ count. * To determine the overall and per patient cost of the incentive intervention model. * To describe associations between adherence measures: real-time medication monitor data, pharmacy pill count, pharmacy prescription pick-up data, medication possession ratio, and self-report. Upon enrollment, participants will receive education and a real-time medication monitor. Participants will be followed monthly in the clinic and will be prescribed thirty-day supplies of medication. During weeks 1-4 participants will establish a baseline with the real-time medication monitor. During weeks 5-28, participants will receive remote incentives based on their level of medication adherence as measured by the real-time medication monitor. Additional lottery-style incentives will occur at regular follow-up visits. No incentives will be applied during weeks 29-48. Participants will complete the protocol at the week 48 visit.
Study Type
OBSERVATIONAL
Enrollment
25
All participants will receive a real-time electronic medication monitor to monitor daily pill-taking behavior. Participants with qualifying levels of adherence will receive a weekly incentive during the intervention period. At all clinic visits participants will participate in a lottery incentive to reinforce clinic attendance and negative STI screening tests.
St. Jude Children's Research Hospital
Memphis, Tennessee, United States
Percentage of dosages taken within 2 hours of prescribed time per month
Data collected by a real-time medication monitor that records pillbox opening times.
Time frame: Monthly through week 48
Pharmacy pill count
Pharmacy pill count data is collected at each participant encounter, approximately once per month.
Time frame: Monthly from 6 months prior to study start through week 48
Feasibility - Accrual percentage
Number of people enrolled in study/number approached for enrollment.
Time frame: End of study (week 48)
Feasibility - Drop out rate
Number of people ending protocol early/ total enrollment
Time frame: End of study (week 48)
Feasibility - Participant reported device concerns
Problems with the Wisepill devices as spontaneously reported by participants or as assessed at routine follow-up.
Time frame: End of study (week 48)
Feasibility - Device replacement rate
Number of devices requiring replacement due to loss/theft/breakage
Time frame: End of study (week 48)
Feasibility - Contact failure rate
Number of failed attempts to contact participants/total number of contact attempts made
Time frame: End of study (week 48)
Feasibility - Staff hours per week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hours spent providing remote incentives
Time frame: End of study (week 48)
Feasibility - Adverse effects of incentives
Unexpected risks/harms of providing incentives as self-reported by participants.
Time frame: End of study (week 48)
Percentage of participants who are satisfied with the incentive intervention
To assess participant satisfaction with the incentive intervention model. Patient satisfaction, assessed by ACASI survey, will be summarized and tabulated for baseline (week 0) and follow-up (week 48) measurements.
Time frame: Enrollment (week 0) and end of study (week 48)
Effect of incentives on missed appointment rate
Descriptive statistics of numbers of missed appointments such as mean, interquartile range and median, during each study phase will be computed and compared
Time frame: Enrollment (week 0) and end of study (week 48)
Effect of incentives on STI rates
Descriptive statistics of numbers of STI rates such as mean, interquartile range and median, during each study phase will be computed and compared
Time frame: Enrollment (week 0) and end of study (week 48)
Change in biological parameters
To measure the effect of the incentive intervention on HIV viral load and CD4+ count. HIV viral load and CD4+ count measured at week 0, 12, 24, 36 and 48 will be summarized and plotted by descriptive statistics, such as mean and standard deviation. Mixed effects models will be applied to explore the effect of the intervention on HIV viral load and CD4+ count.
Time frame: At weeks 0, 12, 24, 36 and 48
Overall cost of incentive intervention
To determine the overall and per patient cost of the incentive intervention model the accumulated overall and per patient cost till week 48 will be summarized and tabulated.
Time frame: End of study (week 48)
Association between adherence measures
To describe associations between adherence measures: Wisepill data, pharmacy pill count, pharmacy prescription pick-up data, medication possession ratio, and self-report. Associations of Wisepill adherence rates with pill count and pick up rates will be described by Pearson or Spearman's correlation coefficients and intraclass correlation coefficients as appropriate.
Time frame: End of study (week 48)